Allogene Therapeutics

Allogene Therapeutics

Yahoo Finance • 28 days ago

Why Avalo Therapeutics, Inc. (AVTX) Is Among the Best Low Priced Stocks to Get Rich in 2026

Avalo Therapeutics, Inc. (NASDAQ:AVTX) is among the best low priced stocks to get rich in 2026. On June 12, BofA started coverage on Avalo Therapeutics, Inc. (NASDAQ:AVTX) with a Buy rating and a price target of $35. According to the firm,... Full story

Yahoo Finance • last month

How Allogene Therapeutics (ALLO) Is Expanding Its Off-the-Shelf CAR T Platform Across Cancer and Autoimmune Disease

Allogene Therapeutics, Inc. (NASDAQ:ALLO) is one of the small-cap stocks with potential to rise 1000 percent. The company's 2026 setup now rests on whether it can turn its off-the-shelf CAR T platform into clinical evidence across both can... Full story

Yahoo Finance • last month

Allogene Therapeutics, Inc. (ALLO) A Top Penny Stock to Buy on Robust CAR T-Cell Portfolio

Allogene Therapeutics, Inc. (NASDAQ:ALLO) is one of the top penny stocks to buy in investors’ stock portfolio. On May 13, Allogene Therapeutics, Inc. (NASDAQ:ALLO) reiterated positive interim results in the ALPHA3 trial of cemacabtagene an... Full story

Yahoo Finance • 2 months ago

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmun... Full story

Yahoo Finance • 3 months ago

William Blair Initiates Natera (NTRA) With Outperform

Natera, Inc. (NASDAQ:NTRA) is one of the Stocks that Billionaire Druckenmiller and Jim Cramer like.William Blair Initiates Natera (NTRA) With Outperform William Blair initiated coverage of Natera, Inc. (NASDAQ:NTRA) with an Outperform rat... Full story

Yahoo Finance • 3 months ago

Allogene Therapeutics (ALLO): 10 Best Growth Stocks Under $10 to Invest In

Allogene Therapeutics Inc. (NASDAQ:ALLO) is one of the best growth stocks under $10 to invest in. On April 21, Allogene Therapeutics received regulatory clearance to expand its pivotal Phase 2 ALPHA3 study of cemacabtagene ansegedleucel (c... Full story

Yahoo Finance • 3 months ago

Wave Life Sciences Ltd. (WVE) Sees Strong Buy Rating From Analysts

Wave Life Sciences Ltd. (NASDAQ:WVE) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The company’s stock registered a 22.39% growth from a year ago and a 53.04% percent decline year-to-date. Based on analyst consen... Full story

Yahoo Finance • 3 months ago

Allogene Prices $175 Mln Offering At $2 Per Share; Stock Down

(RTTNews) - Allogene Therapeutics, Inc. (ALLO) priced the previously announced $175 million public offering of 87.50 million shares at $2.00 per share. The offering is expected to close on or about April 16, 2026. Also, Allogene has grant... Full story

Yahoo Finance • 3 months ago

Allogene Therapeutics Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced the pricing of an underwritten public offering of 87,500,000 shares of its common stock at a price to the public o... Full story

Yahoo Finance • 3 months ago

Allogene Announces $175 Mln Public Offering

(RTTNews) - Allogene Therapeutics Inc. (ALLO), a clinical-stage biotechnology company, on Monday, announced a proposed underwritten public offering of $175 million in shares of the company's common stock. The proceeds from the public offe... Full story

Yahoo Finance • 3 months ago

Why Do Analysts See 180%+ Upside for Allogene Therapeutics (ALLO)?

Allogene Therapeutics, Inc. (NASDAQ:ALLO) secured a spot on our list of the best penny stocks set to explode.Why Do Analysts See 180%+ Upside for Allogene Therapeutics (ALLO)? As of April 8, 2026, analyst sentiment toward Allogene Therape... Full story

Yahoo Finance • 4 months ago

Why Allogene Therapeutics (ALLO) Says Its Lead Cancer Program Is Still on Track in 2026

Allogene Therapeutics, Inc. (NASDAQ:ALLO) is one of the penny stocks with potential to rise 1000 percent. Allogene Therapeutics said on March 12, 2026, that its lead program, cemacabtagene ansegedleucel, or cema-cel, remains on track in t... Full story

Yahoo Finance • 4 months ago

Allogene (ALLO) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, March 12, 2026 at 5 p.m. ET CALL PARTICIPANTS Chief Executive Officer — David ChangChief Medical Officer — Zachary RobertsChief Financial Officer — Geoffrey Parker Need a quote from a Motl... Full story

Yahoo Finance • 5 months ago

Atomera Among 3 Promising Penny Stocks

As February begins, major U.S. stock indexes have shown a robust start with the Dow Jones Industrial Average gaining 515 points and the S&P 500 nearing record highs. In such a buoyant market environment, investors often seek opportunities... Full story

Yahoo Finance • 7 months ago

What a Billionaire Family Office's $16.6 Million Exit From TIC Solutions Signals for Long-Term Investors

Key Points New York City-based Wildcat Capital Management sold 1.5 million shares of TIC in the third quarter. The shares were worth an estimated $16.56 million. The move marked a full exit from TIC, with the stake previously accounting... Full story

Yahoo Finance • 7 months ago

Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis

Arbitration Ruling Reaffirms Allogene’s Full Control of Cemacabtagene Ansegedleucel (Cema-Cel)Decision Reconfirms Allogene’s Expanded Sub-License Covering EU and UK Rights with Options for Japan and China, Clearing the Path for Allogene to... Full story

Yahoo Finance • 7 months ago

December 2025 Penny Stocks Worth Watching

As the U.S. stock market navigates a complex landscape with tech stocks under pressure and indices like the Dow Jones Industrial Average experiencing fluctuations, investors are increasingly exploring diverse opportunities. Penny stocks, o... Full story

Yahoo Finance • 8 months ago

November 2025's Promising Penny Stocks To Watch

As the Dow Jones Industrial Average reaches an all-time high amid optimism over the potential end of a prolonged U.S. government shutdown, investors are keenly observing market dynamics and seeking opportunities across various sectors. Pen... Full story

Yahoo Finance • 8 months ago

Allogene signals pivotal ALPHA3 interim data and ALLO-329 proof-of-concept in first half 2026 while maintaining cash runway into H2 2027

Earnings Call Insights: Allogene Therapeutics (ALLO) Q3 2025 MANAGEMENT VIEW * CEO David Chang emphasized conviction in the company’s allogeneic platform, stating the focus is on “delivering what patients need now” and making “the prom... Full story

Yahoo Finance • 8 months ago

Here are the major earnings after the close Thursday

Major earnings expected after the bell on Thursday include: * Block (XYZ [https://seekingalpha.com/symbol/XYZ]) * The Trade Desk (TTD [https://seekingalpha.com/symbol/TTD]) * Airbnb (ABNB [https://seekingalpha.com/symbol/ABNB]) *... Full story